An attempt by Pfizer to extend the uses of its pulmonary artery hypertension (PAH) drug Revatio into a new paediatric indication has had a major setback. Revatio (sildenafil citrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback